The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know originally appeared on Parade.
You'd be surprised just how contentious a conversation about bagels can get. Sure, they might seem innocuous and like a relatively safe topic of discussion, but if you get the right people in the room, things can go south pretty quickly. Born and raised New Yorkers know a thing or two about where to get the best bagels and you better not even think about scooping out the insides like they do in LA. There are even rules about slicing, and according to some people the water in Jersey makes their bagels the best on the planet. Told you it was a minefield.
😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔
Regardless of how you like your bagel—toasted, schmeared with cream cheese, buttered, or topped with lox—there's no denying that it's one of the greatest grab-and-go breakfasts known to mankind. It's filling and satiating leaving and can easily go from sweet to savory without skipping a beat. No matter what side of the bagel spectrum you fall on, we can all agree, life's sweeter with one in hand.The only thing that could possibly make us put the carby wonders down for good is if, by some chance, the unassuming doughy breakfast companion turned out to be hazardous to our health and the health of those around us. Unfortunately, in the case of Utah-based bagel company New Grains Gluten Free Bakery, it looks like that just might be the case. According to a recent filing by the FDA, the recall was issued due to the undeclared presence of eggs in four varieties of gluten-free bagels—cinnamon raisin, plain, blueberry, and multigrain.
Approximately 100 units of each type were affected by the recall. The recall is listed as Class I, the highest threat level, due to the potential for serious and life-threatening allergic reactions if consumed by someone with an egg allergy. In addition to the bagels, the brand also included artisan white bread, multigrain bread, sourdough, and cinnamon raisin bread in the recall due to the same labeling issue.
The products were distributed between April 4 and 21 under lot numbers 90-107 and were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah, so it seems that the recall is relatively insulated for now. While there have been no reported injuries or illnesses, it's best to avoid consumption if you happen to have purchased one of the affected products. Of course, yours truly isn't allergic to eggs, so I'll make sure to eat one for the both of us bestie.The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know first appeared on Parade on Jun 3, 2025
This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Opinion: When the insulin that works disappears
I remember being in a college pathology class when the professor told us we should learn about type 1 diabetes, since it was likely to impact someone we knew. Then he said something else that I didn't fully understand at the time: the insulin market was becoming more concentrated, with fewer companies producing it, which was leading to fewer options and rising prices. Fast forward nearly 30 years later, and my 13-year-old daughter was diagnosed with type 1 diabetes. We struggled at first. But after a few difficult months, we found a system that worked — involving lifestyle changes and the use of a specific long-acting insulin called Levemir (detemir). Levemir has a shorter and more predictable action than the few alternative long-acting insulins. That made it ideal for my daughter, an athlete navigating not just intense physical activity but also the fluctuating insulin needs that come with puberty and hormone fluctuations. We found a rhythm and felt in control again. Then, two years into her diagnosis, that sense of control was ripped away. On November 8, 2023, we learned that Novo Nordisk planned to discontinue Levemir in the U.S. I was shocked. Levemir had been widely available since 2005. Surely, I thought, someone would step in to fix this. But the more I learned, the more alarmed I became. Levemir is the long-acting insulin that has been most proven safe in pregnancy, where maintaining tight blood glucose control can help prevent early delivery, high blood pressure and large birth weight. Removing it from the market could put pregnant women with diabetes at real risk. I connected with physicians and advocates who were sounding the alarm. I started a petition. I joined with others also affected, and we formed a nonprofit — The Alliance to Protect Insulin Choice — and began traveling to Washington, D.C., often to meet with congressional and regulatory offices. Largely due to our efforts, a company is now seeking to manufacture a biosimilar version of Levemir. But funding has been difficult. Historically, no insulin removed from the market has successfully come back as a biosimilar, and the regulatory path remains unclear. That must change — especially for a drug so critical to pregnancy and pediatric care. Levemir isn't just a niche preference. It was the 127th most prescribed drug and used by just under one million people in 2022. It's still available in other countries. It's the only long-acting insulin that can be diluted, making it vital for infants and small children who need extremely precise doses. It also leads to less weight gain than its alternatives and causes less discomfort during injection because it isn't acidic. The FDA knows that not every drug works the same for every person. Just last year, in response to a penicillin shortage, the agency worked with manufacturers, explored foreign supply chains and increased domestic production. We're asking for the same urgency. We need the FDA to act — to ask Novo Nordisk to permit U.S. access to Levemir from abroad, and to support the company trying to bring a generic version to market. Insulin is not optional. Less than half of people who require insulin use insulin pumps, and many pump users rely on long-acting insulin as a backup. Without Levemir, many patients will be forced onto one of the few alternatives that might not work as well for their bodies and lives. Imagine if a common pain reliever was suddenly pulled from the market — not for safety reasons, but because it was no longer as profitable. There would be outrage. So why is there so little outcry when this happens to a drug that literally keeps people alive? We're asking for fairness, for choice and for a healthcare system that puts patients before profits.
Boston Globe
29 minutes ago
- Boston Globe
RFK Jr. wants to allow more experimental therapies, acknowledging health risks and threat of ‘charlatans'
'And of course you're going to get a lot of charlatans, and you're going to get people who have bad results,' he added. 'And ultimately, you can't prevent that either way. Leaving the whole thing in the hands of pharma is not working for us.' Advertisement Kennedy cited his own experience at a clinic in Antigua, where he said he received a stem cell treatment that 'enormously' eased his neurological condition, spasmodic dysphonia, which affects his voice and has few treatment options. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up If Kennedy does permit broader use of unauthorized or experimental therapies, he would be reversing long-standing efforts by the FDA to monitor and sometimes police the emerging field. Experts, including some who support alternative medicine, worry that without safeguards, an expansion of such treatments could undermine legitimate development of new therapies. The FDA now narrowly permits stem cell therapies to treat blood and immune disorders. Nearly a decade ago, the field was so loosely regulated that the agency pursued court actions to shut down rogue clinics using unauthorized treatments for a wide array of ailments. Some providers in the United States and in other countries continue to offer experimental stem cell therapies for everything from autism to Alzheimer's to erectile dysfunction. Advertisement The latest move reflects an expansion of Kennedy's drive to dismantle federal health policy to reflect his long-held views, which had so far focused mainly on vaccines, chronic diseases, food dyes and fluoride. A push to open up the field of unregulated stem cell infusions meshes with his oft-stated contention that the FDA is a 'sock puppet' for major drug companies and faces a crisis of distrust. Wellness industry products, he has claimed, are unfairly sidelined. A spokesperson for the Department of Health and Human Services did not respond to requests for comment. Kennedy's statements alarmed experts on the field of sometimes dangerous stem cell infusions -- who noted that many of Kennedy's allies endorse wellness products ranging from red-light therapy to magnetism. 'It's a complete abdication of protection of the public, letting these grifters go forward,' said Timothy Caulfield, a research chair in health law and policy at the University of Alberta in Canada. 'For him to say, 'There are problems with Big Pharma, so we want our opportunity to be bad actors too,' it doesn't make any sense.' One leading expert group, the International Society for Stem Cell Research, reviewed Kennedy's podcast statements and condemned the approach as potentially allowing products that are 'sometimes contaminated with pathogens and are often marketed with scientifically implausible claims.' 'It is critical that the FDA maintain its regulatory authority to protect Americans from these potentially harmful and deceptive products,' the society said in a statement. Advertisement On Thursday, a panelist appearing at an FDA meeting on cell and gene therapies raised a concern about 'snake oil' treatments. Dr. Vinay Prasad, the agency's director of the center for biologics evaluation research, responded, 'We have to regulate the bad actors. We can't let that taint what we do here at the FDA.' Kennedy, who also attended the event, voiced full support for the researchers and biotech executives working on gene therapies for rare diseases, including those who made history by creating a custom gene therapy for an infant named KJ. 'We're going to do everything in our power to sweep away the barriers from you getting those solutions to market and getting them funded, and do everything that we can to support you all,' Kennedy said. On Brecka's podcast in May, Kennedy cited other products that he'd like to see more of, including chelation treatment, which was discussed in a 2015 book edited by him that focused on widely debunked theories about mercury in vaccines and autism and cites 'evidence of chelation's benefits' from a few small studies. One 5-year-old Pennsylvania boy died in 2005 from cardiac arrest after a doctor tried to treat his autism with chelation. Neither Kennedy nor the FDA has released a formal plan to change agency standards for stem cell treatments, which have typically been reviewed by the agency as individual therapies to treat a specific disease. Widening overall access could also happen informally if the agency decided to relax enforcement, an approach the FDA used in the past to indicate that it wouldn't crack down on unauthorized products. During the pandemic, for example, the agency allowed providers to retrofit infusion pumps and ventilators to treat hordes of sick patients. Advertisement During the first Trump administration, the agency's commissioner, Dr. Scott Gottlieb, escalated enforcement against stem cell providers whom he described in 2017 as 'unscrupulous actors who have seized on the clinical promise of regenerative medicine.' The FDA followed through with lawsuits seeking to stop some stem cell providers, including one case that the government won on appeal in the fall. In that case, the agency alleged that one provider, the California Stem Cell Treatment Center, was offering a drug without FDA approval by taking stem cells from a person's fat, manipulating them and infusing them as a remedy for Alzheimer's disease, cancer and arthritis. The agency classifies stem cell treatments as a 'biologic' and approves them much like a drug after careful studies of safety and effectiveness. But the FDA does make exceptions: It does not regulate some treatments if providers say they are extracting and then reinserting a person's cells with minimal manipulation. In March, Kennedy convened a meeting with leaders in the stem cell field. Two people who attended said the gathering was a fact-finding effort to explore a safe way to increase access. To Dr. Noah Raizman, who attended the meeting on behalf of the American Academy of Orthopaedic Surgeons, Kennedy's new pronouncement 'sounds a little more casual and a little bit more emboldened.' In the podcast, Kennedy said that consumers should be able to navigate the industry's claims. 'We don't want to have the Wild West,' Kennedy said. 'We want to make sure that information is out there. But we also want to respect the intelligence of the American people -- the capacity of people who explore the outcomes that are going to benefit them the most.' Advertisement In recent years, stem cell treatments have caused harm in the United States and abroad. Experts at the Pew Research Center tallied more than 350 cases of side effects including life-threatening blood infections, heart attacks and tumors. One Boston neurosurgeon discovered a huge mass of bloody tissue in the lower spine of a man who had received unproven stem cell treatments in Mexico, China and Argentina. Three patients were blinded after stem cell treatments at a Florida clinic. The FDA prevailed in getting a court order to stop the clinic from operating. The field of stem cell treatments is so complex that the Harvard Medical School created a free course to help doctors navigate patient questions, said Insoo Hyun, the director of life sciences at the Museum of Science in Boston. More than 110 stem cell clinical studies are advancing under regulatory oversight. In one, scientists at the National Institutes of Health are using retinal cells developed from patients' blood to try to treat vision loss in older adults -- and follow them for 15 years. In another study aimed at helping patients with Parkinson's disease, researchers at a biotech company in California are exploring the safety of infusing dopamine-producing neurons in a region of the brain that controls the body's movements. A Chinese company is studying a treatment for heart failure that involves transplanting cardiac muscle cells into the heart. Some providers sidestep the costly, yearslong process of careful work that can lead to an FDA approval. Among them is Dr. Chadwick Prodromos, a Chicago doctor who offers stem cell treatments in Antigua. Kennedy welcomed him warmly at the March meeting, Raizman recalled. Reached for comment, Prodromos' office said that he was in Antigua doing treatments and was not available. Advertisement In an April interview on YouTube, Prodromos said that he was still in touch with the FDA about stem cell treatments that could help people 'without allowing scams and things that aren't valid. And you know, it's a tricky proposition.' A website for Prodromos' clinic says that he and colleagues offer injections in Antigua into the joints, back, neck, scalp, penis and pelvic floor for an array of conditions including autism, thinning hair and lupus. He uses AlloRX cells, which are derived from the umbilical cord, in a manner that in the United States would require an FDA-cleared clinical trial. People can seek out unregulated treatments using their own cells that are processed, purified and amplified in different ways. They can also find treatments using others' cells that vary widely in quality and sterility. Some low-quality clinics process cells in a back room, which is the opposite of a clinical-grade cell processing site. Hyun said he recently toured one in the Netherlands that used specialized air filtering, layers of gowns and a ban on bacteria-laden cellphones in their sterile area. 'It's kind of like you're entering a space station,' he said. Ultimately, Caulfield said, many unauthorized stem cell providers adopt the language of biotech and regenerative medicine, post glowing patient testimonials and exploit patients who are desperate for a cure. This article originally appeared in .
Yahoo
30 minutes ago
- Yahoo
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial. The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc's (NASDAQ:REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 treatment has been generally well-tolerated to date in this heavily pretreated population. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months. 'This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,' said MAIA Chairman and CEO Vlad Vitoc. MAIA's multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of at least 30%. 'The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,' Vitoc added. Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
